mosunetuzumab + glofitamab + epcoritamab

**mosunetuzumab + glofitamab + epcoritamab** is a hypothetical or experimental combination therapy consisting of three CD20xCD3 bispecific T-cell engaging antibodies: **mosunetuzumab** (Lunsumio), **glofitamab** (Columvi), and **epcoritamab** (Epkinly). Each agent independently redirects T cells to malignant B cells expressing CD20 via CD3 engagement, promoting T-cell-mediated cytotoxicity for B-cell non-Hodgkin lymphomas (B-NHL) such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Developed by Roche/Genentech (mosunetuzumab, glofitamab) and Genmab/AbbVie (epcoritamab), they feature distinct formats—mosunetuzumab (1:1 IgG1 with knobs-into-holes), glofitamab (2:1 CrossMAb with CD20 bivalency), epcoritamab (1:1 DuoBody IgG1 with Fc silencing)—and administration routes (mosunetuzumab/glofitamab IV or SC, epcoritamab SC). No clinical data exists for this specific triplet, though pairwise combinations (e.g., mosunetuzumab + polatuzumab vedotin) show high response rates in R/R MCL; potential for enhanced efficacy via multi-targeting CD20 but increased CRS risk.[1][2][3][4][5]